aidsmap news story
Most people with HIV who received the immune-modulating drug N-803 (Anktiva), with or without broadly neutralising antibodies (bnAbs), did not experience delayed viral rebound after stopping antiretroviral treatment, but they did show some favourable changes in immune response and the viral reservoir, according to a set of posters presented at CROI 2026.
These results – which conflict with findings reported at a conference last year – add to the growing evidence that a combination approach will be needed for a functional cure, or long-term remission without antiretrovirals.
Read the full news story here.
View all aidsmap reports from CROI 2026
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.